Abstract: Acute myeloid leukemia (AML) is a highly heterogeneous hematologic malignancy. In recent years, with the development of chemotherapy, targeted drugs, and hematopoietic stem cell transplantation, the efficacy of treatment for patients with AML has greatly improved; however, most patients remain incurable. The 5-year survival rate of adult patients with AML remains<30%. The efficacy of chimeric antigen receptor (CAR) T-cell therapy for relapsed and refractory B-lymphocyte tumors has been significant, and an increasing number of studies have begun developing the application of CAR T-cell therapy for other types of tumors and diseases. This study reviews the clinical application and research progress of CAR T- cell therapy for AML in recent years.